1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Topics

Showing 23 results.

MCL - 158

Effect of Time to Treatment Initiation in MCL: A SEER Analysis (2000-2022)

Ruby Arora

Poster Presenter: Ruby Arora

Thumbnail for Persistent Gender, Racial, and Urban-Rural Disparities in Mantle Cell Lymphoma Mortality in the United States, 1999-2024: Evidence of Stalled Progress in the Targeted Therapy Era

MCL - 167

Persistent Gender, Racial, and Urban-Rural Disparities in Mantle Cell Lymphoma Mortality in the United States, 1999-2024: Evidence of Stalled Progress in the Targeted Therapy Era

Tapan Giri

Poster Presenter: Tapan Giri

$Thumbnail for Clinical Outcomes Among Patients With Relapsed/Refractory Mantle Cell Lymphoma Receiving Zanubrutinib or Acalabrutinib in Real-World Practice in the United States$

MCL - 178

Clinical Outcomes Among Patients With Relapsed/Refractory Mantle Cell Lymphoma Receiving Zanubrutinib or Acalabrutinib in Real-World Practice in the United States

Javier Munoz

Poster Presenter: Javier Munoz

Video

Thumbnail for Real-World Implementation of the TRIANGLE Regimen in Newly Diagnosed Mantle Cell Lymphoma: A Multicenter Analysis of Effectiveness and Safety

MCL - 322

Real-World Implementation of the TRIANGLE Regimen in Newly Diagnosed Mantle Cell Lymphoma: A Multicenter Analysis of Effectiveness and Safety

Teresa Bedoya Palop

Poster Presenter: Teresa Bedoya Palop

Thumbnail for Trends in Non-Hodgkin Lymphoma Mortality With Concurrent Septicemia in the United States, 1999-2025: A Population-Based CDC WONDER Analysis

MCL - 332

Trends in Non-Hodgkin Lymphoma Mortality With Concurrent Septicemia in the United States, 1999-2025: A Population-Based CDC WONDER Analysis

Ragav Vikraman Thiyagarajan

Poster Presenter: Ragav Vikraman Thiyagarajan

Thumbnail for Benefits of Rituximab Maintenance After First-Line Bendamustine-Rituximab in Mantle Cell Lymphoma: A Meta-Analysis of Clinical Trials and Observational Studies

MCL - 376

Benefits of Rituximab Maintenance After First-Line Bendamustine-Rituximab in Mantle Cell Lymphoma: A Meta-Analysis of Clinical Trials and Observational Studies

Dongni Yi

Poster Presenter: Dongni Yi

Thumbnail for Frontline BTK Inhibitor Strategies in Mantle Cell Lymphoma: A Phase 3 Network Meta-Analysis With Cross-Trial Synthesis Across Transplant-Eligible and -Ineligible Populations

MCL - 522

Frontline BTK Inhibitor Strategies in Mantle Cell Lymphoma: A Phase 3 Network Meta-Analysis With Cross-Trial Synthesis Across Transplant-Eligible and -Ineligible Populations

Sameer Bhimani

Poster Presenter: Sameer Bhimani

Thumbnail for Comparative Cardiac Safety of Covalent and Non-Covalent Bruton Tyrosine Kinase Inhibitors in Mantle Cell Lymphoma- A Multi-Center Retrospective Cohort Study

MCL - 524

Comparative Cardiac Safety of Covalent and Non-Covalent Bruton Tyrosine Kinase Inhibitors in Mantle Cell Lymphoma- A Multi-Center Retrospective Cohort Study

Aditya Anand

Poster Presenter: Aditya Anand

Thumbnail for Updated Results From the Phase 3 ECHO Trial of Bendamustine-Rituximab With or Without Acalabrutinib in Patients With Previously Untreated Mantle Cell Lymphoma: 50 Months of Follow-up

MCL - 575

Updated Results From the Phase 3 ECHO Trial of Bendamustine-Rituximab With or Without Acalabrutinib in Patients With Previously Untreated Mantle Cell Lymphoma: 50 Months of Follow-up

Michael Wang

Poster Presenter: Michael Wang